Table 2.
Univariable and multivariable analysis of overall survival.
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| hazard ratio | 95% CI | p | hazard ratio | 95% CI | p | |
| Age | 0.003 | 0.141 | ||||
| < 65 | 1 | 1 | ||||
| ≥ 65 | 1.34 | 1.10–1.63 | 1.23 | 0.93–1.64 | ||
| Sarcomatoid Feature | 0.018 | 0.003 | ||||
| No | 1 | 1 | ||||
| Yes | 1.41 | 1.06–1.89 | 1.72 | 1.21–2.46 | ||
| Nephrectomy | < 0.001 | 0.018 | ||||
| No | 1.94 | 1.58–2.39 | 1.53 | 1.08–2.22 | ||
| Yes | 1 | 1 | ||||
| Systemic Treatment | 0.034 | 0.704 | ||||
| Sunitinib | 1 | 1 | ||||
| Pazopanib | 1.22 | 1.01–1.48 | 1.05 | 0.79–1.39 | ||
| Anemia | < 0.001 | 0.014 | ||||
| No | 1 | 1 | ||||
| Yes | 1.93 | 1.59–2.35 | 1.41 | 1.07–1.86 | ||
| Hypercalcemia | < 0.001 | 0.894 | ||||
| No | 1 | 1 | ||||
| Yes | 2.21 | 1.52–3.21 | 1.04 | 0.53–2.06 | ||
| LDH Elevation | < 0.001 | 0.190 | ||||
| No | 1 | 1 | ||||
| Yes | 1.97 | 1.47–2.64 | 1.32 | 0.87–2.00 | ||
| ECOG Performance Score | < 0.001 | < 0.001 | ||||
| ECOG 0–1 | 1 | 1 | ||||
| ECOG 2–3-4 | 3.18 | 2.58–3.91 | 2.75 | 2.04–3.71 | ||
| Time to Systemic Treatment | < 0.001 | 0.411 | ||||
| < 1 year | 1.59 | 1.30–1.96 | 1.14 | 0.82–1.59 | ||
| ≥ 1 year | 1 | 1 | ||||
| Previous Cytokine Use | 0.491 | |||||
| No | 1 | |||||
| Yes | 1.06 | 0.88–1.28 | ||||
| Bone or CNS Metastasis | < 0.001 | 0.141 | ||||
| No | 1 | 1 | ||||
| Yes | 1.60 | 1.28–2.00 | 1.23 | 0.93–1.64 | ||
| Number of Systemic Treatment* | 0.061 | 0.289 | ||||
| 1 | 1.19 | 0.99–1.44 | 1.16 | 0.88–1.52 | ||
| > 1 | 1 | 1 | ||||
| SII | < 0.001 | 0.018 | ||||
| Low | 1 | 1 | ||||
| High | 1.70 | 1.40–2.08 | 1.41 | 1.06–1.87 | ||
CI confidence interval, CNS central nervous system, ECOG eastern cooperative oncology group, LDH lactate dehydrogenase, SII systemic immune-inflammation index.
Significant values are in bold.
*Except for interferon.